# Histoindex Pte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/histoindex-pte

- Industry: Healthcare IT
- Headquarters: Singapore, Singapore
- Website: www.histoindex.com
- Total disclosed funding: $5M
- Latest round: Series A (Jun 6, 2021)
- Investors on record: 5

## About

Based in Singapore, and founded in 2010 by CEO Gideon HO, and CSO Dean TAI, Histoindex Pte Ltd., d.b.a. Histoindex operates as a med-tech company that specializes in AI (artificial intelligence)-based stain-free digital pathology solutions, focusing on the accurate assessment of nonalcoholic steatohepatitis (NASH). In May 2025, Histoindex raised SGD 9 million in venture funding led by new investor investor OCBC. Returning investors ZIG Ventures and SEEDS Capital also participated in the round. The product line of Histoindex includes Genesis 200, a quantitative, stain-free, automated, multi-organ, 2D and 3D multiphoton imaging system used in clinical trials and preclinical studies for drug development of NASH (Nonalcoholic Steatohepatitis), and HistoHepa, a suite of image analysis tools that generate objective and accurate quantification to improve liver diseases’ diagnosis and assessment. In addition, the company also offers multiple services, such as data management, tissue morphological analysis, 2D / 3D visualization, cell and collagen quantification, image analysis package, and tissue imaging services. The company plans to utilize the May 2025 funding to create next-generation AI-powered SHG digital pathology tests for MASH patients and support its growing network of partnered laboratories and operations in the US.

## Funding rounds

- Series A, Jun 6, 2021, $3.5M — SEEDS Capital, ZIG Ventures, Aligent Spring, Syntech Engineers, Pathomics Health Pte Ltd
- Series A, Sep 20, 2016, $1.4M — SEEDS Capital, ZIG Ventures

## Investors

- SEEDS Capital (https://capitalatlas.ai/funds/seeds-capital) — Series A
- ZIG Ventures (https://capitalatlas.ai/funds/zig-ventures) — Series A
- Aligent Spring — Series A
- Syntech Engineers — Series A
- Pathomics Health Pte Ltd — Series A